You are here
Therapeutic Potential of Refanalin in Pulmonary Fibrosis
Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL076959-01A1
Agency Tracking Number: HL076959
Amount:
$175,272.00
Phase:
Phase I
Program:
SBIR
Solicitation Topic Code:
N/A
Solicitation Number:
PHS2004-2
Timeline
Solicitation Year:
2004
Award Year:
2004
Award Start Date (Proposal Award Date):
N/A
Award End Date (Contract End Date):
N/A
Small Business Information
ANGION BIOMEDICA CORP
350 COMMUNITY DR, RM 129
MANHASSET, NY
11030
United States
DUNS:
N/A
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: LATHA Paka
Phone: (516) 562-1278
Email: SPAKA@ANGION.COM
Phone: (516) 562-1278
Email: SPAKA@ANGION.COM
Business Contact
Name: ITZHAK GOLDBERG
Phone: (516) 869-6400
Email: GOLDBERG@ANGION.COM
Phone: (516) 869-6400
Email: GOLDBERG@ANGION.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a devastating disease with less than a 50% five-year survival. While steroids and other immunosuppressive agents serve as the standard treatment for IPF, these agents have pro
* Information listed above is at the time of submission. *